REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies intended to affect disease. The company is headquartered in Rockville, Maryland.
| Revenue (TTM) | $174.48M |
| Gross Profit (TTM) | $-78.42M |
| EBITDA | $-148.78M |
| Operating Margin | 27.10% |
| Return on Equity | -137.60% |
| Return on Assets | -21.20% |
| Revenue/Share (TTM) | $3.34 |
| Book Value | $1.32 |
| Price-to-Book | 6.89 |
| Price-to-Sales (TTM) | 2.71 |
| EV/Revenue | 2.626 |
| EV/EBITDA | -3.37 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 405.70% |
| Shares Outstanding | $66.01M |
| Float | $57.23M |
| % Insiders | 6.55% |
| % Institutions | 65.07% |
Volatility is currently expanding
Event to include clinical program overview and perspectives from leading retina specialists ahead of topline pivotal data readout anticipated in 4Q 2026 ROCKVILLE, Md., Oct. 12, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will host an investor event at 1:00 p.m.
Majority of Dose Level 3 participants with NPDR demonstrated a > 2-step DRSS improvement at 3 years post-one-time, in-office sura-vec gene therapy treatment, with no vision-threatening events and no additional treatment for diabetic retinopathy No IOI observed with short-course prophylactic topical steroids ROCKVILLE, Md., Sept. 24, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced positive long-term follow-up data from the Phase II ALTITUDE® study of investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314) in diabetic retinopathy (DR) using suprachoroidal delivery.
REGENXBIO Inc. (RGNX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
ROCKVILLE, Md., Sept. 8, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: Baird 2026 Global Healthcare Conference Fireside Chat: Tuesday, September 15 at 8:30 a.m.
REGENXBIO stock plunges 25% after the FDA places a clinical hold on RGX-121 for MPS II, following asymptomatic spine MRI findings in five participants.
Regenxbio is rated a 'risky buy' due to high volatility, regulatory setbacks, and significant near-term catalysts. RGNX faces a clinical hold on RGX-121 for Hunter Syndrome, complicating milestone payments and royalty streams, but maintains sufficient cash runway into Q4 2027. Pivotal data for the AbbVie-partnered eye disease program and BLA submission for RGX-202 in DMD represent major binary catalysts by year-end and 2027.
ROCKVILLE, Md., Aug. 25, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Greg Ciongoli to its Board of Directors, effective August 25, 2026.
SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating REGENXBIO Inc. (NASDAQ: RGNX) on behalf of investors who suffered losses and whether those losses may be recoverable under federal securities laws. If you purchased REGENXBIO securities and suffered losses, click here to join the investigation.
Regenxbio reports the discovery of nodules and masses on the spines of patients enrolled in a trial for RGX-121, the company's investigational therapy for Hunter syndome.
ROCKVILLE, Md., Aug. 24, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today provided an update on its investigational gene therapy, RGX-121 (clemidsogene lanparvovec), for the treatment of Mucopolysaccharidosis type II (MPS II), also known as Hunter Syndrome.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on RGNX and any ticker you trade — then tracks every position and per-strategy win rate.
